Objectives: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by theWHO as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dose-dependent haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisininresistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status. Methods and analysis: In this prospective, fourarmed randomised pl...
Contains fulltext : 109283.pdf (publisher's version ) (Open Access)ABSTRACT: Follo...
Background: This study assessed the safety of the new World Health Organization (WHO) recommendation...
ABSTRACT: Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocid...
OBJECTIVES: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to...
Objectives: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to...
BACKGROUND: Primaquine is the only available drug that clears mature Plasmodium falciparum gametocyt...
Background: Primaquine is the only available drug that clears mature Plasmodium falciparum gametocyt...
SummaryBackgroundPrimaquine is the only available drug that clears mature Plasmodium falciparum game...
Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected ...
Contains fulltext : 88117.pdf (publisher's version ) (Open Access)The current inte...
Background: Primaquine is a pro-drug and its active metabolite is potent against mature Plasmodium f...
Contains fulltext : 171512.pdf (publisher's version ) (Open Access)BACKGROUND: A s...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Contains fulltext : 109283.pdf (publisher's version ) (Open Access)ABSTRACT: Follo...
Background: This study assessed the safety of the new World Health Organization (WHO) recommendation...
ABSTRACT: Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocid...
OBJECTIVES: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to...
Objectives: For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to...
BACKGROUND: Primaquine is the only available drug that clears mature Plasmodium falciparum gametocyt...
Background: Primaquine is the only available drug that clears mature Plasmodium falciparum gametocyt...
SummaryBackgroundPrimaquine is the only available drug that clears mature Plasmodium falciparum game...
Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected ...
Contains fulltext : 88117.pdf (publisher's version ) (Open Access)The current inte...
Background: Primaquine is a pro-drug and its active metabolite is potent against mature Plasmodium f...
Contains fulltext : 171512.pdf (publisher's version ) (Open Access)BACKGROUND: A s...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Background: In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/k...
Contains fulltext : 109283.pdf (publisher's version ) (Open Access)ABSTRACT: Follo...
Background: This study assessed the safety of the new World Health Organization (WHO) recommendation...
ABSTRACT: Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocid...